RBC Europe’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

RBC Europe’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-875	Closed	-$1.26K	–	1169
2017 Q3	$1.26K	Buy	+875	New	+$1.24K	﹤0.01%	1073

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

RBC Europe's ANTH Position: Q4 2017 in Review

RBC Europe sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 875 shares — an estimated $1.26K sold.

RBC Europe first reported a position in ANTH in Q3 2017 and held it in 1 quarter. The position peaked at $1.26K in Q3 2017. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

RBC Europe reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
RBC Europe sold 875 Anthera Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.26K.
RBC Europe first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
RBC Europe's Anthera Pharmaceuticals, Inc. position peaked at $1.26K in Q3 2017.
37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on RBC Europe's 13F filing for Q4 2017, filed 9 Nov 2023.